TrialClinical cancer research : an official journal of the American Association for Cancer Research2026
Circulating Thymidine Kinase Activity Predicts Survival and Optimal Treatment Sequencing in BRAF-Mutated Metastatic Melanoma in the SECOMBIT Trial.
Hildur Helgadottir et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.